PR
PRAX.US Praxis Precision Medicines Inc
- Market cap
- USD 8.53B
- P/E
- -
- P/B
- 6.89x
- ROE
- -28.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PRAX.US undervalued?
Graham numberThe Graham number of Praxis Precision Medicines Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Praxis Precision Medicines Inc fundamental analysis
No fundamental analysis for Praxis Precision Medicines Inc yet.
Praxis Precision Medicines Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacal…
Full company profilePraxis Precision Medicines Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Praxis Precision Medicines Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.46M | 2.45M | 8.55M | 0.00 | 0.00 |
| Gross Profit | -1.00K | -679K | -746K | -1.59M | -1.17M | -84.3M | -144M | -140K | - |
| Operating Income | -22.7M | -35.8M | -62.0M | -167M | -215M | -126M | -200M | -326M | -413M |
| EBITDA | -26.3M | -34.9M | -61.9M | -167M | -215M | -123M | -182M | -303M | -361M |
| Net Income | -26.5M | -35.5M | -61.8M | -167M | -213M | -123M | -183M | -303M | -361M |
| EPS | -30 | -31 | -24 | -59 | -69 | -19 | -10 | -13 | -12 |
| Balance Sheet | |||||||||
| Total Assets | 19.8M | 47.7M | 303M | 293M | 115M | 87.9M | 483M | 938M | 1.31B |
| Total Liabilities | 5.15M | 7.58M | 15.7M | 41.9M | 39.0M | 18.3M | 37.7M | 59.8M | 52.5M |
| Shareholders' Equity | 14.7M | 40.1M | 287M | 251M | 76.1M | 69.7M | 445M | 878M | 1.26B |
| Cash & Short-term Investments | 18.0M | 44.8M | 297M | 276M | 100M | 81.3M | 393M | 599M | 745M |
| Total Debt | - | 1.46M | 763K | 4.31M | 4.51M | 2.50M | 1.37M | 110K | 732K |
| Cash Flow | |||||||||
| Operating Cash Flow | -20.7M | -32.8M | -52.6M | -125M | -185M | -111M | -132M | -249M | -327M |
| Capital Expenditure | 63.0K | 103K | 4.00K | 1.05M | 444K | 50.0K | 0.00 | 56.0K | 1.45M |
| Free Cash Flow | -20.8M | -32.9M | -52.6M | -126M | -185M | -111M | -132M | -249M | -329M |
| Ratios | |||||||||
| ROE | -180.7% | -88.5% | -21.5% | -66.5% | -280.0% | -176.9% | -41.0% | -34.5% | -28.6% |
| ROA | -133.8% | -74.5% | -20.4% | -57.0% | -185.1% | -140.2% | -37.8% | -32.3% | -27.5% |
| Net Profit Margin | - | - | - | - | -14,554.1% | -5,037.9% | -2,137.5% | - | - |
| Debt to Equity | - | 0.04x | 0.00x | 0.02x | 0.06x | 0.04x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Praxis Precision Medicines Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 811K | 0.26 | - |
| 2021 | - | - | - |
| 2020 | USD 696K | 0.27 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:15 on Nov 29, 2023.
Who owns Praxis Precision Medicines Inc
- Insiders 0.28%
- Institutions 99.72%
- Public & others 0.00%
- Shares outstanding 28.0M
- Free float 24.1M
Top funds holding PRAX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 887K | 3.18% | +0.02% | Sep 2026 |
| iShares Russell 2000 ETF | 637K | 2.28% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 628K | 2.25% | -2.08% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 459K | 1.64% | +2.68% | Oct 2026 |
| Polar Capital Biotech S Inc | 417K | 1.49% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 411K | 1.47% | 0.00% | Aug 2026 |
| Vanguard MStar Small Cap Value Index | 385K | 1.38% | +0.42% | Sep 2026 |
| Janus Henderson Global Life Sciences D | 384K | 1.37% | +6.37% | Sep 2026 |
| Janus Global Life Science AUSD | 374K | 1.34% | +4.60% | Sep 2026 |
| Janus Henderson Enterprise D | 358K | 1.28% | 0.00% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 347K | 1.24% | -3.87% | Aug 2026 |
| Orbis Global Equity Investor | 333K | 1.19% | -41.23% | Jun 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 291K | 1.04% | +2.97% | Jun 2026 |
| Fidelity Small Cap Index | 275K | 0.98% | +0.14% | Aug 2026 |
| Janus Henderson Triton D | 248K | 0.89% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 236K | 0.85% | -0.38% | Oct 2026 |
| T. Rowe Price New Horizons | 227K | 0.81% | -11.02% | Sep 2026 |
| Orbis SICAV Global Bal Instl Inv | 212K | 0.76% | +63.43% | Mar 2026 |
| iShares Biotechnology ETF | 205K | 0.73% | -0.19% | Oct 2026 |
| Franklin DynaTech Fund A | 200K | 0.72% | +13.09% | Sep 2026 |
Top institutions holding PRAX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jupiter Topco LLC | 3.42M | 12.24% | 0.00% | Jun 2026 |
| FMR Inc | 2.32M | 8.29% | +7.22% | Jun 2026 |
| BlackRock Inc | 2.29M | 8.20% | -1.39% | Jun 2026 |
| Perceptive Advisors LLC | 2.04M | 7.28% | 0.00% | Jun 2026 |
| Baker Bros Advisors LP | 1.75M | 6.27% | 0.00% | Jun 2026 |
| Orbis Allan Gray Ltd | 1.53M | 5.47% | -38.13% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.34M | 4.78% | +76.44% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.24M | 4.42% | +1.09% | Jun 2026 |
| State Street Corp | 1.03M | 3.67% | +16.08% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.02M | 3.63% | +24.49% | Jun 2026 |
| Deerfield Management Co | 963K | 3.45% | 0.00% | Jun 2026 |
| Driehaus Capital Management LLC | 959K | 3.43% | +1.03% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 943K | 3.37% | +49.48% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 854K | 3.06% | +2.47% | Jun 2026 |
| Geode Capital Management, LLC | 748K | 2.68% | +14.92% | Jun 2026 |
| Cormorant Asset Management, LLC | 640K | 2.29% | -27.72% | Jun 2026 |
| The Goldman Sachs Group Inc | 549K | 1.96% | -22.78% | Jun 2026 |
| Bank of America Corp | 547K | 1.96% | +2.31% | Jun 2026 |
| Amvescap Plc. | 538K | 1.92% | +775.53% | Jun 2026 |
| Hood River Capital Management LLC | 425K | 1.52% | +18.56% | Jun 2026 |
Praxis Precision Medicines Inc company profile
- Company name
- Praxis Precision Medicines Inc
- Ticker
- PRAX.US
- Exchange
- USA Stocks
- Listed since
- Oct 16, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 168
- Fiscal year end
- December
- Address
- 99 High Street, Boston, MA, United States, 02110
- Phone
- 617 300 8460
- Website
- praxismedicines.com
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Praxis Precision Medicines Inc management
10- Mr. Marcio Silva De'Souza M.B.A.President, CEO & Director · born 1979
- Mr. Timothy Edwin KellyCFO & Treasurer · born 1973
- Mr. Alex Nemiroff J.D.General Counsel & Secretary · born 1979
- Dr. Steven Petrou B.Sc. (Hons.), Ph.D.Co-Founder and President of Research & Development
- Ms. Megan T. SniecinskiChief Operating Officer · born 1981
- Dr. Karl Hansen Ph.D.Chief Technical Operations Officer
- Ms. Kelly McCueChief People Officer
- Ms. Alyssa J. S. WyantChief Regulatory & Quality Officer · born 1975
- Mr. Brian SparChief of Staff
- Dr. Orrin Devinsky M.D., Ph.D.Head of Clinical Strategy · born 1958